Cargando…

Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis

BACKGROUND: Progressive fibrous thickening of the peritoneal membrane is a complication of long-term peritoneal dialysis (PD). TGF-β/Smad pathway activation, inflammation, and neoangiogenesis play important roles in peritoneal membrane (PM) changes induced by PD. Recently, histone deacetilase inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Costalonga, Elerson C., de Freitas, Luiza J., Aragone, Deise da S. P., Silva, Filipe M. O., Noronha, Irene L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584960/
https://www.ncbi.nlm.nih.gov/pubmed/28873458
http://dx.doi.org/10.1371/journal.pone.0184302
_version_ 1783261535618990080
author Costalonga, Elerson C.
de Freitas, Luiza J.
Aragone, Deise da S. P.
Silva, Filipe M. O.
Noronha, Irene L.
author_facet Costalonga, Elerson C.
de Freitas, Luiza J.
Aragone, Deise da S. P.
Silva, Filipe M. O.
Noronha, Irene L.
author_sort Costalonga, Elerson C.
collection PubMed
description BACKGROUND: Progressive fibrous thickening of the peritoneal membrane is a complication of long-term peritoneal dialysis (PD). TGF-β/Smad pathway activation, inflammation, and neoangiogenesis play important roles in peritoneal membrane (PM) changes induced by PD. Recently, histone deacetilase inhibitors (HDACi) have shown anti-fibrotic and anti-inflammatory effects in different experimental models. These drugs prevent deacetylation of histones causing a loosen chromatin, which in turn induce the expression of some anti-fibrotic genes. In addition, acetylation may increase the activity of proteins involved in tissue fibrosis, such as Smad7. Here, we explored the effect of valproic acid (VPA), an HDACi, on the development of peritoneal fibrosis (PF) in rats. METHODS: PF was induced by daily intraperitoneal injections of 0.1% chlorhexidine gluconate (CG) for 15 consecutive days. Male Wistar rats (250–300 g) were divided into 3 groups: CONTROL, control rats receiving only vehicle; PF, peritoneal fibrosis induced in rats; PF+VPA, rats with PF treated with VPA (300 mg/kg/day by gavage). PF was assessed by Masson’s trichrome staining. Inflammation and fibrosis-associated factors were assessed by immunohistochemistry, immunofluorescence, multiplex analysis, and qPCR. RESULTS: Treatment with VPA significantly reduced PM thickness and the expression of myofibroblasts, besides preventing loss of ultrafiltration capacity of the PM. The upregulation of profibrotic factors (TGF-β, fibronectin, and Smad3) in the PF group was significantly ameliorated by VPA. VPA modulated the TGF/Smad pathway, inhibiting phosphorylated Smad3 expression and inducing an increased Smad7 expression in the FP+VPA group. The neoangiogenesis and the expression of proinflammatory cytokines (TNF-α, IL-1β, MCP-1) observed in the PF group was significantly reduced by VPA. CONCLUSIONS: Our results indicate that VPA suppressed experimental PF through modulation of the TGF-β/Smad pathway. Interestingly, VPA treatment induced a higher expression of antifibrotic factors, such as Smad7. These results suggest that VPA may represent a potential strategy for treating long term PD complications.
format Online
Article
Text
id pubmed-5584960
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55849602017-09-15 Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis Costalonga, Elerson C. de Freitas, Luiza J. Aragone, Deise da S. P. Silva, Filipe M. O. Noronha, Irene L. PLoS One Research Article BACKGROUND: Progressive fibrous thickening of the peritoneal membrane is a complication of long-term peritoneal dialysis (PD). TGF-β/Smad pathway activation, inflammation, and neoangiogenesis play important roles in peritoneal membrane (PM) changes induced by PD. Recently, histone deacetilase inhibitors (HDACi) have shown anti-fibrotic and anti-inflammatory effects in different experimental models. These drugs prevent deacetylation of histones causing a loosen chromatin, which in turn induce the expression of some anti-fibrotic genes. In addition, acetylation may increase the activity of proteins involved in tissue fibrosis, such as Smad7. Here, we explored the effect of valproic acid (VPA), an HDACi, on the development of peritoneal fibrosis (PF) in rats. METHODS: PF was induced by daily intraperitoneal injections of 0.1% chlorhexidine gluconate (CG) for 15 consecutive days. Male Wistar rats (250–300 g) were divided into 3 groups: CONTROL, control rats receiving only vehicle; PF, peritoneal fibrosis induced in rats; PF+VPA, rats with PF treated with VPA (300 mg/kg/day by gavage). PF was assessed by Masson’s trichrome staining. Inflammation and fibrosis-associated factors were assessed by immunohistochemistry, immunofluorescence, multiplex analysis, and qPCR. RESULTS: Treatment with VPA significantly reduced PM thickness and the expression of myofibroblasts, besides preventing loss of ultrafiltration capacity of the PM. The upregulation of profibrotic factors (TGF-β, fibronectin, and Smad3) in the PF group was significantly ameliorated by VPA. VPA modulated the TGF/Smad pathway, inhibiting phosphorylated Smad3 expression and inducing an increased Smad7 expression in the FP+VPA group. The neoangiogenesis and the expression of proinflammatory cytokines (TNF-α, IL-1β, MCP-1) observed in the PF group was significantly reduced by VPA. CONCLUSIONS: Our results indicate that VPA suppressed experimental PF through modulation of the TGF-β/Smad pathway. Interestingly, VPA treatment induced a higher expression of antifibrotic factors, such as Smad7. These results suggest that VPA may represent a potential strategy for treating long term PD complications. Public Library of Science 2017-09-05 /pmc/articles/PMC5584960/ /pubmed/28873458 http://dx.doi.org/10.1371/journal.pone.0184302 Text en © 2017 Costalonga et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Costalonga, Elerson C.
de Freitas, Luiza J.
Aragone, Deise da S. P.
Silva, Filipe M. O.
Noronha, Irene L.
Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis
title Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis
title_full Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis
title_fullStr Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis
title_full_unstemmed Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis
title_short Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis
title_sort anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584960/
https://www.ncbi.nlm.nih.gov/pubmed/28873458
http://dx.doi.org/10.1371/journal.pone.0184302
work_keys_str_mv AT costalongaelersonc antifibroticeffectsofvalproicacidinexperimentalperitonealfibrosis
AT defreitasluizaj antifibroticeffectsofvalproicacidinexperimentalperitonealfibrosis
AT aragonedeisedasp antifibroticeffectsofvalproicacidinexperimentalperitonealfibrosis
AT silvafilipemo antifibroticeffectsofvalproicacidinexperimentalperitonealfibrosis
AT noronhairenel antifibroticeffectsofvalproicacidinexperimentalperitonealfibrosis